China vs Ethiopia: Average cost of multi drug-resistant tuberculosis treatment
China
20,028 constant 2022 US$
in 2024
Ethiopia
5,583 constant 2022 US$
in 2024
China rank
4th
Ethiopia rank
7th
Average cost of multi drug-resistant tuberculosis treatment over time
- China
- Ethiopia
How they compare
China currently reports 20,028 constant 2022 US$ against 5,583 constant 2022 US$ in Ethiopia, a difference of 14,445 constant 2022 US$.
That makes China's figure about 3.6 times Ethiopia's.
The two have swapped places 1 time across 7 shared years of data; in 2017 it was Ethiopia ahead.
China ranks 4th and Ethiopia ranks 7th of 92 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | Ethiopia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,878 constant 2022 US$ | 3,815 constant 2022 US$ | 1,064 constant 2022 US$ | China |
| 2020s | 20,415 constant 2022 US$ | 5,661 constant 2022 US$ | 14,754 constant 2022 US$ | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, China or Ethiopia?
- China, at 20,028 constant 2022 US$ against 5,583 constant 2022 US$ in Ethiopia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between China and Ethiopia?
- 14,445 constant 2022 US$, with China ahead.
- How many years of comparable data are there for China and Ethiopia?
- 7 years are reported by both, from 2017 to 2024.
- How do China and Ethiopia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- China ranks 4th and Ethiopia ranks 7th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.